Zacks Investment Research
21 Jul 2026, 14:51 UTC · 4h ago
Boston Scientific's Q2 Earnings Coming Up: Buy, Hold or Sell the Stock?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
21 Jul 2026, 14:51 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Boston Scientific currently carries a Zacks Rank #4 (Sell). — A 'Sell' rating from a quantitative model suggests negative short-term outlook or relative underperformance.
-0.30Boston Scientific is scheduled to report Q2 2026 earnings on July 29, with a consensus EPS estimate of 83 cents and revenue estimate of $5.39 billion. — Provides the baseline expectations for a major medical device company's upcoming earnings report.
+0.20Management previously indicated the Endoscopy business would face AXIOS-related impacts and transient supply-chain disruptions in Q2 2026. — Identifies specific operational headwinds that could drag down revenue or margins in a key business segment.
-0.20Continue reading
6 related stories
Top 3 movers · tap to explore
The Urology segment's soft performance, impacted by China's volume-based procurement program, is likely to have persisted into the second quarter. — Highlights a continuing drag on performance due to regulatory and procurement pressures in the Chinese market.
Which stocks this story touches
The company has a Zacks Rank #4 (Sell) and faces transient supply-chain disruptions and headwinds in China.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
3h ago
